More than 3,500 college athletes with a confirmed COVID-19 diagnosis were included in the new study. The median follow-up period was more than one full year. 

MAVD patients did face a higher risk of requiring a permanent pacemaker, researchers noted, though the reason for this trend remains unclear. 

CT-FFR, which recently got a boost from the 2021 AHA/ACC chest pain guidelines, could play a key role for clinicians hoping to screen TAVR patients for coronary heart disease. 

“Our results are relevant to clinical practice, supporting the use of the Mediterranean diet in secondary prevention," researchers wrote. 

The median time from heart valve implantation to balloon dilatation was 4.6 months.

“Improving ancillary shielding barriers is paramount,” according to the authors of a brand new analysis. 

Hello Heart, a digital therapeutics company that focuses on heart health, has raised $70 million in a Series D funding round.

The trial is expected to enroll up to 650 patients from as many as 100 different facilities throughout the world.

Engineers detailed their prototype, which is roughly the size of a small stack of quarters, in Nature Biomedical Engineering.

The study's authors tracked data from six different randomized controlled trials, including a large study from 2021 that focused on myocardial infarction patients.